Peptides II: Metabolism, Aging & Cognition, Where the Evidence Stands

Peptide conversations have moved well beyond recovery. Metabolic support, healthy aging, and cognition are drawing growing interest too, and the research behind each compound looks very different. In our second peptide session, Rex Jones walks through MOTS-c, Epitalon, and Semax, including the pathways they're thought theoretically to act on and which findings come from lab and animal studies versus people.

You'll also hear the key cautions for each compound, how current FDA guidance applies, and why a dosing reference in a study isn't a ready-made protocol.

This webinar is designed for:

• Functional and integrative medicine providers evaluating peptide research
• Longevity and metabolic health clinicians looking for a clear read on the research
• Providers interested in cognition-related peptide research
• Prescribers seeking context on risks, regulatory status, and common dosing

You’ll learn how to:

• Differentiate the research on MOTS-c, Epitalon, and Semax across metabolism, aging, and cognition
• Explain proposed signaling pathways and identify which findings come from laboratory or animal studies
• Recognize key risks and the limits of published human evidence for each peptide
• Put FDA guidance and dosing references in context, without mistaking them for approval or established protocols
  
  Disclaimer:

This information is intended for educational purposes only and does not constitute medical or legal advice. Clinical decisions remain the responsibility of the prescriber. Prescribers should use their independent clinical judgment when determining appropriate care.

Compounded medications are specially prepared for identified individual patient needs based on a valid prescription from a prescribing healthcare practitioner and, as such, are not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. Compounded drugs are intended for patients whose prescriber has determined their medical needs are not met by an available FDA-approved drug. These statements have not been evaluated by the FDA.

Any discussion of peptides is intended for educational purposes only and should not be interpreted as claims regarding the safety or efficacy of any compounded preparation. Strive does not compound peptides for patient use without FDA authorization and regulatory clearance of the applicable APIs. Production of peptides is entirely contingent on the FDA's regulatory posture and formal guidance. Strive will follow the FDA's lead.